BioRestorative Therapies (BRTX) Retained Earnings (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Retained Earnings came in at $170.3 million in Q4 2025, up 209.37% YoY from $55.0 million in Q4 2024, and up 0.8% on a QoQ basis from $168.9 million in Q3 2025.
BioRestorative Therapies (BRTX) Retained Earnings (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Retained Earnings data on file, last reported at $170.3 million in Q4 2025.
- Quarterly Retained Earnings rose 209.37% year-over-year to $170.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $170.3 million (up 209.37% YoY) and the FY2025 annual result came in at $170.3 million, up 209.37% from the prior year.
- Retained Earnings advanced to $170.3 million in Q4 2025, from $168.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $170.3 million in Q4 2025 to a low of -$163.7 million in Q2 2025.
- A 5-year average of -$638885.5 and a median of -$5.6 million in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 226.63% in 2021, down 265.25% in 2021.
- Tracing BRTX's Retained Earnings over 5 years: stood at -$134.1 million in 2021, then surged by 209.25% to $146.6 million in 2022, then advanced by 6.91% to $156.7 million in 2023, then sank by 199.36% to -$155.7 million in 2024, then jumped by 209.37% to $170.3 million in 2025.
- The last three Retained Earnings figures came in at $170.3 million (Q4 2025), $168.9 million (Q3 2025), and -$163.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 170.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 170.26 Mn |
| Sep 30, 2025 | 168.91 Mn |
| Jun 30, 2025 | -163.67 Mn |
| Mar 31, 2025 | -161.02 Mn |
| Dec 31, 2024 | -155.68 Mn |
| Sep 30, 2024 | -154.04 Mn |
| Jun 30, 2024 | -152.95 Mn |
| Mar 31, 2024 | 163.41 Mn |
| Dec 31, 2023 | 156.69 Mn |
| Sep 30, 2023 | -144.40 Mn |
| Jun 30, 2023 | -149.16 Mn |
| Mar 31, 2023 | 149.90 Mn |
| Dec 31, 2022 | 146.56 Mn |
| Sep 30, 2022 | 143.38 Mn |
| Jun 30, 2022 | -128.17 Mn |
| Mar 31, 2022 | 137.20 Mn |
| Dec 31, 2021 | -134.15 Mn |
| Sep 30, 2021 | -113.74 Mn |
| Jun 30, 2021 | 105.42 Mn |
| Mar 31, 2021 | 102.48 Mn |